drugset
drugset / Trial / NCT01238042

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

NCT01238042 ↗

Phase 1 Completed 18 enrolled Roswell Park Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

Patient's with High Grade Dysplasia, Carcinoma in situ or Early Adenocarcinoma in Barrett's Esophagus are injected with HPPH and one day later are endoscopically treated with light from a laser.

Timeline

Start
2003-03
Primary completion
2004-10
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown 3 mg/m2 Other
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown 4 mg/m2 Other

Indications

Barrett esophagus